Newsroom | 23463 results

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it filed its unaudited financial results for the six months ended June 30, 2026 with the U.S. Securities and Exchange Commission. An electronic copy of the financial results can be accessed at the Company’s website at www.sinovac.com and at the SEC’s website www.sec.gov. First Half of 2026 Financial Summary Sales for the six months...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax, commonly called New World screwworm (NWS), feed on living tissues, such as open wounds, of animals including livestock, wildlife and pets, and can inflict da...

IRVINE, Calif.--(BUSINESS WIRE)--AIVITA Biomedical named a 2026 Prix Galien USA "Best Startup" nominee for its personalized cancer immunotherapy platform....

SAN FRANCISCO--(BUSINESS WIRE)--The Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF) today announced the appointment of Brad Schneider, Ph.D., as Chief Operating Officer. Dr. Schneider brings more than two decades of experience in infectious disease research, global health operations, and scientific program leadership to his new role. "Brad brings something rare to QBI, a scientist's instincts and an operator's discipline," said Nevan J. Krogan, Ph....

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), een biotechnologiebedrijf in een gevorderd klinisch stadium dat zich toelegt op de preventie en behandeling van door Bordetella pertussis veroorzaakte ziekten, kondigde vandaag de benoemingen aan van Jim Wassil, momenteel Chief Operating Officer van Vaxcyte; Suha Jhaveri, voormalig Strategisch Adviseur van Cidara vóór de overname ervan door Merck; en Bill Warren, voormalig Global Head of Antigen Design van Sanofi Vaccines, als...

WESTON, Florida--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), empresa biotecnológica en fase clínica avanzada centrada en la prevención y el tratamiento de enfermedades causadas por Bordetella pertussis, ha anunciado hoy el nombramiento de Jim Wassil, actual director de operaciones de Vaxcyte; Suha Jhaveri, exasesora estratégica de Cidara antes de su adquisición por Merck; y Bill Warren, exresponsable mundial de diseño de antígenos de Sanofi Vaccines, como miembros independientes de su...

WESTON, Flo.--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), une société de biotechnologie au stade clinique avancé spécialisée dans la prévention et le traitement des maladies causées par Bordetella pertussis, a annoncé aujourd’hui la nomination de Jim Wassil, actuellement directeur des opérations chez Vaxcyte ; Suha Jhaveri, ancienne conseillère stratégique chez Cidara avant son rachat par Merck ; et Bill Warren, ancien responsable mondial de la conception d’antigènes chez Sanofi Vacci...

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the company’s infectious disease therapies, XACDURO® (sulbactam/durlobactam for injection), ZEVTERA® (ceftobiprole medocaril sodium for injection), and NUZOLVENCE® (zoliflodacin) are finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year an Innoviva Specialty Therapeutics prod...

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the second quarter ended June 30, 2026. “AN2 will have three Phase 2 programs underway by the end of this year, all of which have the potential to address major unmet needs. Our near-term focus is advancing start-up activi...

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), società biotecnologica all'avanguardia di fase clinica incentrata sulla prevenzione e sul trattamento della malattia causata da Bordetella pertussis, oggi ha annunciato le nomine di Jim Wassil, attualmente Direttore delle operazioni per Vaxcyte; Suha Jhaveri, ex Consulente strategico per Cidara prima dell'acquisizione da parte di Merck; e Bill Warren, già Responsabile globale di Antigen Design per Sanofi Vaccines, come membri i...